Ascent Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ascent Pharmaceuticals, founded in 2003 and headquartered in Cranford, New Jersey, is a private company specializing in the generic and specialty pharmaceutical market. It leverages a development and commercialization model to bring lower-cost generic drugs to market, addressing the need for affordable medicines in the United States. The company appears to be revenue-generating, given its commercial focus on established generic products. Its strategic position relies on navigating complex regulatory pathways and competing effectively in the crowded but essential generic drug landscape.

Generic Drugs

Technology Platform

Integrated generic drug development platform encompassing formulation science, bioequivalence testing, regulatory strategy (ANDA filings), and commercial manufacturing.

Opportunities

The ongoing need for affordable medication and waves of patent expiries for blockbuster drugs create a steady stream of potential generic targets.

Focusing on complex generics or niche therapeutic areas can offer higher margins and less competition than simple commodity generics.

Risk Factors

Extreme price competition and consolidation in the generic market severely pressure profitability.

Regulatory hurdles and patent litigation can delay product launches and incur significant costs, while supply chain dependencies introduce quality and availability risks.

Competitive Landscape

Ascent operates in the highly fragmented and competitive U.S. generic pharmaceutical industry, competing against large multinational generics firms (e.g., Teva, Sandoz, Mylan) and numerous smaller private companies. Competition is primarily on price, regulatory execution speed, and product selection.

More companies in Small Molecule Drugs →More companies in United States →